Viking Therapeutics, Inc. (VKTX): Shareholders' Equity
$639.06M
As of 2025-12-31
$408.32M
As of 2026-06-30
+63.8%
3-year compound annual growth
+21.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $639.06M | -27.4% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $880.28M | +152.6% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $348.42M | +139.8% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $145.32M | -28.0% | 2024-02-07, Balance as of period end |
| 2021-12-31 | $201.88M | -17.4% | 2023-02-10, Balance as of period end |
| 2020-12-31 | $244.34M | -11.8% | 2022-02-09, Balance as of period end |
| 2019-12-31 | $277.12M | -6.9% | 2021-02-17, Balance as of period end |
| 2018-12-31 | $297.75M | n/m | 2020-02-26, Balance as of period end |
| 2017-12-31 | $13.46M | +67.4% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $8.04M | -7.8% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $8.72M | n/m | 2017-03-21, Balance as of period end |
| 2014-12-31 | -$22.13M | n/a | 2016-03-08, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $639.06M | -27.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare VKTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗